AU2002222930A1 - Cyclic amine phenyl beta-3 adrenergic receptor agonists - Google Patents
Cyclic amine phenyl beta-3 adrenergic receptor agonistsInfo
- Publication number
- AU2002222930A1 AU2002222930A1 AU2002222930A AU2293002A AU2002222930A1 AU 2002222930 A1 AU2002222930 A1 AU 2002222930A1 AU 2002222930 A AU2002222930 A AU 2002222930A AU 2293002 A AU2293002 A AU 2293002A AU 2002222930 A1 AU2002222930 A1 AU 2002222930A1
- Authority
- AU
- Australia
- Prior art keywords
- receptor agonists
- adrenergic receptor
- cyclic amine
- phenyl beta
- amine phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Fodder In General (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21862700P | 2000-07-17 | 2000-07-17 | |
US60218627 | 2000-07-17 | ||
PCT/US2001/022387 WO2002006232A1 (en) | 2000-07-17 | 2001-07-16 | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002222930A1 true AU2002222930A1 (en) | 2002-01-30 |
Family
ID=22815833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002222930A Abandoned AU2002222930A1 (en) | 2000-07-17 | 2001-07-16 | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
Country Status (10)
Country | Link |
---|---|
US (2) | US6525202B2 (en) |
EP (1) | EP1301482A1 (en) |
JP (1) | JP2004504299A (en) |
CN (1) | CN1455771A (en) |
AR (1) | AR032624A1 (en) |
AU (1) | AU2002222930A1 (en) |
BR (1) | BR0112522A (en) |
CA (1) | CA2416245A1 (en) |
MX (1) | MXPA03000518A (en) |
WO (1) | WO2002006232A1 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1242083B1 (en) * | 1999-12-17 | 2007-03-14 | Sanofi-Aventis | Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them |
US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
US6498170B2 (en) | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
US6410734B1 (en) * | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
US6525202B2 (en) * | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
US7071220B2 (en) * | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
US6909515B2 (en) | 2001-01-22 | 2005-06-21 | Cyberoptics Corporation | Multiple source alignment sensor with improved optics |
SE0100902D0 (en) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0100903D0 (en) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
BE1014245A4 (en) * | 2001-04-03 | 2003-07-01 | Malak Jean | Chemical compounds octopamine derivatives and uses thereof as agonists beta 3-adrenergic. |
SE0103710D0 (en) * | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
SE0202539D0 (en) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
US7521465B2 (en) * | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
AR042941A1 (en) | 2003-01-27 | 2005-07-06 | Fujisawa Pharmaceutical Co | DERIVATIVES OF TIAZOL, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF INHIBITING MEDICINES OF VASCULAR ADHESION PROTEIN-1 (VAP-1) |
DE10306250A1 (en) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals |
US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
EP1479677A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
WO2004108674A1 (en) * | 2003-06-05 | 2004-12-16 | Kissei Pharmaceutical Co., Ltd. | Amino alcohol derivative, medicinal composition containing the same, and uses of these |
DE10351271A1 (en) * | 2003-10-31 | 2005-06-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical composition for the treatment of stress incontinence and / or mixed incontinence |
US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
SE0401762D0 (en) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
RU2391340C2 (en) * | 2004-08-11 | 2010-06-10 | Киорин Фармасьютикал Ко., Лтд. | Novel cyclic derivative of aminobenzoic acid |
SE0403086D0 (en) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
SE0403085D0 (en) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
KR20070116644A (en) * | 2005-03-23 | 2007-12-10 | 교린 세이야꾸 가부시키 가이샤 | Novel cyclic aminophenylalkanoic acid derivative |
AU2006300877A1 (en) | 2005-10-13 | 2007-04-19 | Orchid Research Laboratories Limited | Heterocyclic compounds as pSTAT3/IL-6 inhibitors |
TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
MX337100B (en) * | 2007-10-05 | 2016-02-11 | Acucela Inc | Alkoxy compounds for disease treatment. |
PE20091825A1 (en) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR |
CN105418450A (en) | 2008-05-05 | 2016-03-23 | 赛诺菲-安万特 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
US8618144B2 (en) | 2009-05-08 | 2013-12-31 | Merck Sharp & Dohme Corp | Pyrrolidine-derived beta 3 adrenergic receptor agonists |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
AR079022A1 (en) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | DERIVATIVES OF CYCLIC CARBOXYL ACID SUBSTITUTED WITH ACILAMINE, ITS USE AS PHARMACEUTICAL PRODUCTS, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD |
PE20131341A1 (en) | 2010-08-03 | 2013-12-07 | Altherx Inc | COMBINATIONS OF BETA-3-ADRENERGIC RECEPTOR AGONISTS AND MUSCARINIC RECEPTOR ANTAGONISTS TO TREAT HYPERACTIVE BLADDER |
US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
US8546443B2 (en) | 2010-12-21 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Benzylic oxindole pyrimidines |
ES2584427T3 (en) | 2011-10-27 | 2016-09-27 | Merck Sharp & Dohme Corp. | Process for the preparation of beta 3 agonists and intermediate products |
JP6063948B2 (en) | 2011-10-27 | 2017-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Process for producing beta 3 agonists and intermediates |
DK2968269T3 (en) | 2013-03-15 | 2019-10-07 | Merck Sharp & Dohme | PROCEDURE FOR PREPARING BETA-3 AGONISTS AND INTERMEDIATES |
KR20170086659A (en) | 2014-12-03 | 2017-07-26 | 벨리셉트 테라퓨틱스, 인크. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
FI3365321T3 (en) | 2015-10-23 | 2024-01-02 | B3Ar Therapeutics Inc | Solabegron zwitterion and uses thereof |
AU2018282104B2 (en) | 2017-06-06 | 2024-07-11 | Urovant Sciences Gmbh | Use of vibegron to treat overactive bladder |
CN107215770A (en) * | 2017-06-27 | 2017-09-29 | 中国煤炭科工集团太原研究院有限公司 | The multiple degrees of freedom gib head of mining hydraulic winch |
EP4076423A4 (en) * | 2019-12-19 | 2024-03-13 | Casma Therapeutics, Inc. | Trpml modulators |
EP4404924A1 (en) * | 2021-09-23 | 2024-07-31 | Curasen Therapeutics, Inc. | Beta adrenergic agonist and methods of using the same |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4348393A (en) | 1978-06-09 | 1982-09-07 | Delalande S.A. | N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones |
EP0089154A3 (en) | 1982-03-12 | 1984-08-08 | Beecham Group Plc | Ethanolamine derivatives, their preparation and use in pharmaceutical compositions |
GB2163150B (en) | 1984-07-19 | 1988-05-25 | Sandoz Ltd | 3-aminopropoxyaryl derivatives |
GB8528633D0 (en) | 1985-11-21 | 1985-12-24 | Beecham Group Plc | Compounds |
US4813998A (en) | 1986-02-27 | 1989-03-21 | Janssen Pharmaceutica N.V. | Herbicidal 1H-imidazole-5-carboxylic acid derivatives |
US5143928A (en) | 1990-03-27 | 1992-09-01 | Warner-Lambert Company | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents |
EP0449261A3 (en) | 1990-03-29 | 1992-02-26 | Kabushiki Kaisha Toshiba | Resin composition for an optical disc and an optical disc using it |
DE4117904A1 (en) * | 1991-05-31 | 1992-12-03 | Basf Ag | SUBSTITUTED N-PHENYLPIPERIDINES |
EP0590793B1 (en) | 1992-08-31 | 1999-10-13 | Sankyo Company Limited | Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses |
US5998452A (en) | 1993-06-23 | 1999-12-07 | Chugai Seiyaku Kabushiki Kaisha | Benzene derivatives, compositions and methods for treating ischemic diseases |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
TW363959B (en) | 1994-03-23 | 1999-07-11 | Sankyo Co | Thiazolidine and oxazolidine derivatives, their preparation and their medical use |
IL113410A (en) | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
US5561142A (en) | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5789402A (en) | 1995-01-17 | 1998-08-04 | Eli Lilly Company | Compounds having effects on serotonin-related systems |
US5614523A (en) | 1995-01-17 | 1997-03-25 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5741789A (en) | 1995-01-17 | 1998-04-21 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
HUP9802318A3 (en) * | 1995-10-26 | 2001-04-28 | Mitsubishi Tokyo Pharm Inc | Phenylethanolamine derivatives, process for producing the same, and intermediates in the production of the same |
EP0801060A1 (en) | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
EP0906310A4 (en) | 1996-06-07 | 1999-09-01 | Merck & Co Inc | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE -g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
WO1997041120A1 (en) | 1996-07-26 | 1997-11-06 | Dr. Reddy's Research Foundation | Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof |
EP0827746B1 (en) | 1996-09-05 | 2002-04-03 | Eli Lilly And Company | Carbazole analogues as selective beta3 adrenergic agonists |
WO1998022480A1 (en) | 1996-11-18 | 1998-05-28 | Smithkline Beecham Plc | Phosphorus containing aryloxy or arylthio propanolamine derivatives |
WO1998032753A1 (en) | 1997-01-28 | 1998-07-30 | Merck & Co., Inc. | THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
US6150378A (en) | 1997-10-07 | 2000-11-21 | Cephalon, Inc. | Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors |
PT1028111E (en) | 1997-10-17 | 2004-09-30 | Yamanouchi Pharma Co Ltd | DERIVATIVES OF AMIDA OR ITS SALTS |
FR2780057B1 (en) | 1998-06-18 | 2002-09-13 | Sanofi Sa | PHENOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US6214842B1 (en) | 1999-05-12 | 2001-04-10 | Michael S. Malamas | Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia |
FR2798126B1 (en) | 1999-09-08 | 2001-10-19 | Sanofi Synthelabo | HETEROARYLOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
EP1242083B1 (en) * | 1999-12-17 | 2007-03-14 | Sanofi-Aventis | Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them |
FR2802533B1 (en) | 1999-12-17 | 2002-02-15 | Sanofi Synthelabo | PHENOXYPROPANOLAMINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
US6444685B1 (en) * | 2000-07-17 | 2002-09-03 | Wyeth | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
US6514991B2 (en) | 2000-07-17 | 2003-02-04 | Wyeth | Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists |
US6509358B2 (en) | 2000-07-17 | 2003-01-21 | Wyeth | Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
US6395762B1 (en) | 2000-07-17 | 2002-05-28 | American Home Products Corporation | Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
US6458817B1 (en) | 2000-07-17 | 2002-10-01 | Wyeth | Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists |
US6451814B1 (en) | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
US6498170B2 (en) | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
US6506901B2 (en) | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
-
2001
- 2001-07-12 US US09/903,754 patent/US6525202B2/en not_active Expired - Fee Related
- 2001-07-16 AU AU2002222930A patent/AU2002222930A1/en not_active Abandoned
- 2001-07-16 BR BR0112522-2A patent/BR0112522A/en not_active Application Discontinuation
- 2001-07-16 EP EP01984234A patent/EP1301482A1/en not_active Withdrawn
- 2001-07-16 AR ARP010103382A patent/AR032624A1/en unknown
- 2001-07-16 CA CA002416245A patent/CA2416245A1/en not_active Abandoned
- 2001-07-16 JP JP2002512136A patent/JP2004504299A/en active Pending
- 2001-07-16 WO PCT/US2001/022387 patent/WO2002006232A1/en not_active Application Discontinuation
- 2001-07-16 MX MXPA03000518A patent/MXPA03000518A/en unknown
- 2001-07-16 CN CN01815504A patent/CN1455771A/en active Pending
-
2002
- 2002-12-27 US US10/330,576 patent/US7022716B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6525202B2 (en) | 2003-02-25 |
US20030144326A1 (en) | 2003-07-31 |
CA2416245A1 (en) | 2002-01-24 |
EP1301482A1 (en) | 2003-04-16 |
WO2002006232A1 (en) | 2002-01-24 |
JP2004504299A (en) | 2004-02-12 |
US20020028835A1 (en) | 2002-03-07 |
US7022716B2 (en) | 2006-04-04 |
BR0112522A (en) | 2003-06-24 |
AR032624A1 (en) | 2003-11-19 |
CN1455771A (en) | 2003-11-12 |
MXPA03000518A (en) | 2003-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002222930A1 (en) | Cyclic amine phenyl beta-3 adrenergic receptor agonists | |
AU2002222932A1 (en) | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | |
AU2001280568A1 (en) | Heterocyclic beta-3 adrenergic receptor agonists | |
AU2002222929A1 (en) | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | |
DE60232171D1 (en) | ARYLANILIN BETA-2 ADRENERGIC RECEPTOR AGONIST | |
IL154911A0 (en) | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists | |
AU2001247372A1 (en) | 5-amide substituted diarylamines as mex inhibitors | |
GB0130003D0 (en) | Web-based dating service | |
IL152528A0 (en) | Beta3 adrenergic agonists | |
HK1091403A1 (en) | 5-ht 1a receptor subtype agonist | |
HK1069111A1 (en) | Pharmaceutical composition comprising a 5ht1 receptor agonist. | |
HK1073312A1 (en) | Cyclic amine compound | |
AU2001273508A1 (en) | Heterocyclic beta-3 adrenergic receptor agonists | |
AU2003212310A1 (en) | (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors | |
AU2001273542A1 (en) | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | |
IL158051A0 (en) | Somatostatin agonists | |
AU2002328576A1 (en) | Cyclic amine compound | |
AU2001276936A1 (en) | Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists | |
AU2001286409A1 (en) | N-methyl-d-aspartate receptor antagonists | |
DE60224326D1 (en) | Network facsimile machine | |
AU2001273501A1 (en) | Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists | |
PL372467A1 (en) | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | |
GB0023467D0 (en) | Amine compounds | |
AU2002355928A1 (en) | Beta3 adrenergic agonists | |
ZA200005850B (en) | β2- Adrenergic receptor agonists. |